Comment on Zamfir et al. Hematologic Malignancies Diagnosed in the Context of the mRNA COVID-19 Vaccination Campaign: A Report of Two Cases. Medicina 2022, 58, 874

Abstract

The SARS-CoV-2 spike protein mRNA-based vaccines have prevented countless mortality and morbidity, and have an excellent risk/benefit ratio. However, various adverse events may rarely occur after the BNT162b2 vaccine, like any other medical intervention. The COVID-19 itself and the spike protein produced endogenously by mRNA vaccines may have immunological, microenvironmental, prothrombotic, and neoplastic effects. As a contribution to the published report, we would like to share our experience regarding four cases in which myeloid neoplasms emerged following the vaccination. Conclusions: There is no doubt that vaccination could continue along the lines of established universal recommendations. Meanwhile, all hematological adverse events must be closely monitored and reported. Further efforts should be focused on the probable pathobiological mechanisms and causalities of spike protein-related toxicity and clonal myeloid disorders.

A Case Report of Acute Lymphoblastic Leukaemia (ALL)/Lymphoblastic Lymphoma (LBL) Following the Second Dose of Comirnaty®: An Analysis of the Potential Pathogenic Mechanism Based on of the Existing Literature

“…The development and widespread use of modRNA vaccines have raised significant concerns globally, leading to adverse events and complications in both healthy individuals and those with preexisting conditions. Reports of increased cases of a variety of cancers [18], including highly aggressive cancers, termed "Turbo Cancer" [20] and the unexpected recurrence of cancers after decades of remission, have been independently noted by oncology experts and researchers worldwide, with several publications supporting these observations [35][36][37][38][39][40][41][42][43][44][45][46][47][48][49][50][51]. Understanding the mechanisms behind the carcinogenic effects of the modRNA COVID-19 vaccines is crucial.…”

Ph-Positive B-Cell Acute Lymphoblastic Leukemia Occurring after Receipt of Bivalent SARS-CoV-2 mRNA Vaccine Booster: A Case Report

“…Only seven cases of hematologic malignancy occurrence post mRNA COVID-19 vaccinations were reported to date [ 7 , 8 , 9 ]. All of the seven cases received monovalent BNT162b2 (Pfizer-BioNTech) vaccine inoculations.…”

“…Although they have shown effectiveness in reducing COVID-19-related mortality and morbidity [ 2 , 3 , 4 , 5 ], many concerns about the safety of these vaccines were generated regarding their novel genetic technology and materials [ 6 ]. Sporadic hematopoietic adverse events were reported [ 7 , 8 , 9 , 10 ]. The bivalent formulations of BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) COVID-19 vaccines, which can induce remarkably high levels of anti-spike protein antibodies, have demonstrated their significant efficacy against the Omicron variant and acceptable safety in clinical practice [ 11 ].…”

“…Many researchers have provided strong support for the safety and benefits of COVID-19 vaccination [ 2 , 3 , 4 , 5 , 11 , 24 ], but several authors implied immune cell stimulation might be the trigger of the hematologic adverse events after COVID-19 vaccination [ 7 , 8 , 9 , 10 , 25 , 26 ]. An intense vaccination campaign for herd immunity to against SARS-CoV-2 infection is mandatory, however, it is a continuous process for collecting the safety data of these vaccines, especially the current worldwide used booster bivalent formulations of BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) COVID-19 vaccines.…”

Rare COVID-19 vaccine side effects got lost in the shuffle. Primary cutaneous lymphomas following COVID-19 vaccination: a systematic review

“…According to data, the majority of side effects of mRNA COVID-19 vaccines are mild to moderate, including fever, fatigue, headache, muscle ache, and cutaneous manifestations at the injection site (3,4,6,7). However, various rare cases of new-onset or flare of immune-mediated diseases, as well as hematologic malignancies and primary cutaneous lymphomas (CLs), have been reported (8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22).…”